Small Molecules for RNA-mediated Diseases
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
12
NCT03959189
Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1
Phase: Phase 1
Role: Lead Sponsor
Start: Jun 17, 2019
Completion: Apr 30, 2020
Loading map...